The Personalized-Medication Adherence and Persistence Program (P-MAPP) is the FIRST national initiative, built in collaboration with patients, prescribers, pharmacists, pharmaceutical companies, payers and regulators, that impacts real-world clinical and economic outcomes for patients with Type 2 Diabetes.
Tracks changes in HbA1c, kidney function, lipids, blood pressure, weight and
integrates with data from patients’ medical records, pharmacy and claims data, and importantly
harnesses the Voice of the Patient, using customized surveys to capture drivers of nonadherence behavior.
Pharmacists counsel patients on personalized and sustainable strategies to improve adherence and impact outcomes.